Open Access Article March 7, 2025

6 Pages

Eptifibatide Induced Thrombocytopenia in Acute Coronary Syndrome: A Real-World Data

Authors

Zubair Shahid1 , Ahmed Mahfouz2 , Ashraf Ahmed3,* , Alaa Rahhal4 , Dina Soliman5 , Mariam Imran6 , Elmustafa Abdalla7, Unus Bedardeen8, Mohammed Elmurtada9 , Firyal Ibrahim10 , Mohamed Yassin11 , Shehab Mohamed12

  1. Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
  2. Pharmacy Department, Hamad Medical Corporation, Doha, Qatar
  3. Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, CT, USA
  4. Pharmacy Department, Hamad Medical Corporation, Doha, Qatar
  5. Laboratory Department hematopathology, Hamad Medical Corporation, Doha, Qatar
  6. Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar
  7. Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar
  8. Department of Cardiology, Heart Hospital, Hamad Medical Corporation, Doha
  9. Department of Haematology, NCCCR, Hamad Medical Corporation, Doha
  10. Laboratory Department hematopathology, Hamad Medical Corporation, Doha, Qatar
  11. Department of Haematology, NCCCR, Hamad Medical Corporation, Doha, Qatar
  12. Department of Haematology, NCCCR, Hamad Medical Corporation, Doha, Qatar
  13. * Author to whom correspondence should be addressed.

Journal of Heart Valve Disease Innovation 2025, 30(1), 01-06; https://doi.org/10.36923/jhvd.v30i1.245

Download PDF Share Ask AI (Dimensions)

Abstract

Background: Eptifibatide is a known antiplatelet that is used in patients undergoing percutaneous coronary intervention for ACS, and it is proven to have a positive outcome. Despite thrombocytopenia not being reported in the pivotal trials, the emerging literature associated this link. We aim to further investigate this association and provide real-world data from a single centre. Methods: A retrospective study was conducted in Heart Hospital at Hamad Medical Corporation from 2016 to 2022. All patients admitted with ACS and received Eptifibatide were included in the study. Patients with confirmed secondary causes of thrombocytopenia were excluded. The data is reported in the form of mean, median, standard deviation, interquartile range, and percentage. Results: Twenty-six patients met the inclusion criteria, with an average age of 54 ± 11 years, and all patients were males. The baseline platelets count was 157 ± 80, and haemoglobin was 14 ± 2. Fourteen patients had platelets drop by more than 50% of their baseline. Thrombocytopenia developed after eptifibatide infusion by 36 ± 29. The average haemoglobin post-eptifibatide infusion was 13.5 ± 1.7 g/dL. Three patients required platelet transfusion, 23 patients were managed conservatively, and one patient died. Conclusion: Eptifibatide can cause life-threatening thrombocytopenia, which can be simply reversed by ceasing the infusion. However, platelet transfusion might be necessary in some patients. Neither the mechanism nor the risk factors are clear, and further studies are recommended to understand this association better.

Article information

Keywords
Eptifibatideglycoprotein IIb/IIIa receptor inhibitorAcute coronary syndromeThrombocytopenia
Section
Articles
Issue
Vol. 30 No. 1 (2025)
Submitted
September 11, 2024
Accepted
January 10, 2025
Published
March 7, 2025
Corresponding author
Ashraf Ahmed
Check for updates
Check for updates

References

  1. 1. Bansal AB, Sattar Y, Jamil RT. Eptifibatide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Pub-lishing; 2024 [cited 2024 Mar 19]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK541066/ Google Scholar PubMed WorldCat
  2. 2. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2023 Oct 7;44(38):3720–826. Google Scholar PubMed WorldCat
  3. 3. O’Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA. 2001 May 16;285(19):2468–73. DOI: https://doi.org/10.1001/jama.285.19.2468 Google Scholar PubMed WorldCat
  4. 4. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 1997 May 17;349(9063):1422–8. DOI: https://doi.org/10.1016/S0140-6736(96)10172-0 Google Scholar PubMed WorldCat
  5. 5. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997 Aug 18;80(4A):11B-20B. DOI: https://doi.org/10.1016/S0002-9149(97)00572-9 Google Scholar PubMed WorldCat
  6. 6. PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evalu-ation (PRICE) Trial. Am Heart J. 2001 Mar;141(3):402–9. DOI: https://doi.org/10.1067/mhj.2001.113391 Google Scholar PubMed WorldCat
  7. 7. Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes. New England Journal of Medicine. 1998 Aug 13;339(7):436–43. DOI: https://doi.org/10.1056/NEJM199808133390704 Google Scholar PubMed WorldCat
  8. 8. Tempelhof MW, Benzuly KH, Fintel D, Krichavsky MZ. Eptifibatide-Induced Thrombocytopenia. Tex Heart Inst J. 2012;39(1):86–91. Google Scholar PubMed WorldCat
  9. 9. Fahdi IE, Saucedo JF, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004 Feb 15;93(4):453–5. DOI: https://doi.org/10.1016/j.amjcard.2003.10.041 Google Scholar PubMed WorldCat
  10. 10. Kamar K, MacDougall K, Alsheikh M, Parylo S, Skaradinskiy Y. A rare case of eptifibatide-induced throm-bocytopenia. J Community Hosp Intern Med Perspect. 2021 Mar 23;11(2):269–72. DOI: https://doi.org/10.1080/20009666.2021.1871802 Google Scholar PubMed WorldCat
  11. 11. Byrd G, Custovic S, Byrd D, Ingrassia Miano D, Bathla J, Attallah A. Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage. Case Rep Crit Care. 2021;2021:8817067. DOI: https://doi.org/10.1155/2021/8817067 Google Scholar PubMed WorldCat
  12. 12. Saglio G, Yassin M, Alhuraiji A, Lal A, Alam A, Khan F, et al. Current Status and Management of Chronic Myeloid Leukemia in the Gulf Region: Survey Results and Expert Opinion. Cancers (Basel). 2024 May 31;16(11):2114. DOI: https://doi.org/10.3390/cancers16112114 Google Scholar PubMed WorldCat
  13. 13. Complications and Management of Eptifibatide-Induced Thrombocytopenia - Faisal Masood, Saad Hashmi, Adib Chaus, Anna Hertsberg, Eli D. Ehrenpreis, 2021 [Internet]. [cited 2024 Mar 21]. Available from: https://journals-sagepub-com.qulib.idm.oclc.org/doi/10.1177/10600280211006645 Google Scholar PubMed Crossref WorldCat
  14. 14. Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes | NEJM [Internet]. [cited 2024 Mar 20]. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa0901316 Google Scholar PubMed Crossref WorldCat
  15. 15. Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. European Heart Journal. 2005 Oct 1;26(19):1971–7. DOI: https://doi.org/10.1093/eurheartj/ehi293 Google Scholar PubMed WorldCat
  16. 16. Eptifibatide-associated acute, profound thrombocytopenia - PubMed [Internet]. [cited 2024 Mar 21]. Availa-ble from: https://pubmed-ncbi-nlm-nih-gov.qulib.idm.oclc.org/15644467/ Google Scholar PubMed WorldCat
  17. 17. Pothineni NV, Watts TE, Ding Z, Dai Y, Deshmukh AJ. Eptifibatide-Induced Thrombocytopenia--When Inhibitor Turns Killer. Am J Ther. 2016;23(1):e298-299. DOI: https://doi.org/10.1097/01.mjt.0000438283.01797.1a Google Scholar PubMed WorldCat
  18. 18. Refaat M, Smith AJC, Edmundowicz D. Eptifibatide-induced thrombocytopenia. J Thromb Thrombolysis. 2008 Apr;25(2):204–6. DOI: https://doi.org/10.1007/s11239-007-0166-x Google Scholar PubMed WorldCat
  19. 19. Epelman S, Nair D, Downey R, Militello M, Askari AT. Eptifibatide-induced thrombocytopenia and throm-bosis. J Thromb Thrombolysis. 2006 Oct;22(2):151–4. DOI: https://doi.org/10.1007/s11239-006-8785-1 Google Scholar PubMed WorldCat
  20. 20. Huffman T, Gleaves E, Lenoir G, Rafeedheen R. Delayed-onset eptifibatide-induced thrombocytopenia. Am J Health Syst Pharm. 2024 Feb 8;81(4):106–11. DOI: https://doi.org/10.1093/ajhp/zxad271 Google Scholar PubMed WorldCat
  21. 21. Puram RV, Erdil RM, Weber BN, Knelson EH, Van Beuningen AM, Wallwork R, et al. Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies. Thromb Haemost. 2020 Jul;120(7):1137–41. DOI: https://doi.org/10.1055/s-0040-1712458 Google Scholar PubMed WorldCat
  22. 22. Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Acti-vating Antiplatelet Antibodies - PubMed [Internet]. [cited 2024 Mar 21]. Available from: https://pubmed-ncbi-nlm-nih-gov.qulib.idm.oclc.org/32483771/ Google Scholar PubMed WorldCat
  23. 23. Tempelhof MW, Benzuly KH, Fintel D, Krichavsky MZ. Eptifibatide-Induced Thrombocytopenia. Tex Heart Inst J. 2012;39(1):86–91. Google Scholar PubMed WorldCat
  24. 24. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, et al. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359–62. DOI: https://doi.org/10.1016/S0021-9258(18)92826-7 Google Scholar PubMed WorldCat
  25. 25. Fahdi IE, Saucedo JF, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2004 Feb 15;93(4):453–5. DOI: https://doi.org/10.1016/j.amjcard.2003.10.041 Google Scholar PubMed WorldCat
  26. 26. Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol. 1999 Jul;61(3):205–8. DOI: https://doi.org/10.1002/(SICI)1096-8652(199907)61:3<205::AID-AJH8>3.3.CO;2-0 Google Scholar PubMed WorldCat
  27. 27. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, et al. Abciximab readministra-tion: results of the ReoPro Readministration Registry. Circulation. 2001 Aug 21;104(8):870–5. DOI: https://doi.org/10.1161/hc3301.094533 Google Scholar PubMed WorldCat
  28. 28. Rikken SAOF, van ’t Hof AWJ, ten Berg JM, Kereiakes DJ, Coller BS. Critical Analysis of Thrombocyto-penia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Mol-ecule Glycoprotein Inhibitor, in Understanding the Mechanism(s). Journal of the American Heart Associa-tion. 2023 Dec 19;12(24):e031855. DOI: https://doi.org/10.1161/JAHA.123.031855 Google Scholar PubMed WorldCat
  29. 29. Sharma A, Ferguson C, Bainey KR. Thrombocytopenia in acute coronary syndromes: etiologies and pro-posed management. Can J Cardiol. 2015 Jun;31(6):809–11. DOI: https://doi.org/10.1016/j.cjca.2014.12.034 Google Scholar PubMed WorldCat
  30. 30. Tardiff BE, Jennings LK, Harrington RA, Gretler D, Potthoff RF, Vorchheimer DA, et al. Pharmacodynam-ics and Pharmacokinetics of Eptifibatide in Patients With Acute Coronary Syndromes. Circulation. 2001 Jul 24;104(4):399–405. DOI: https://doi.org/10.1161/hc2901.093500 Google Scholar PubMed WorldCat
  31. 31. Gheith Z, Kilani A, Nguyen T. Eptifibatide-Induced Severe Thrombocytopenia After ST-Elevation Myocar-dial Infarction (STEMI): A Case Report. Cureus. 2022 Sep;14(9):e29549. DOI: https://doi.org/10.7759/cureus.29549 Google Scholar PubMed WorldCat
  32. 32. Alamin MA, Al-Mashdali A, Al Kindi DI, Elshaikh EA, Othman F. Eptifibatide-induced acute profound thrombocytopenia: A case report. Medicine (Baltimore). 2022 Oct 21;101(42):e28243. DOI: https://doi.org/10.1097/MD.0000000000028243 Google Scholar PubMed WorldCat
  33. 33. Graidis C, Golias C, Dimitriadis D, Dimitriadis G, Bitsis T, Dimitrelos I, et al. Eptifibatide-induced acute profound thrombocytopenia: a case report. BMC Res Notes. 2014 Feb 25;7:107. DOI: https://doi.org/10.1186/1756-0500-7-107 Google Scholar PubMed WorldCat
  34. 34. Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immedi-ately after left main coronary artery percutaneous coronary angioplasty - PubMed [Internet]. [cited 2024 Mar 21]. Available from: https://pubmed-ncbi-nlm-nih-gov.qulib.idm.oclc.org/22412237/ Google Scholar PubMed WorldCat
  35. 35. Giuliano C, Edwin SB, Kador H, Mooney M. Eptifibatide-Induced Thrombocytopenia and Subsequent Thrombosis. Journal of Pharmacy Technology. 2012 Jul 1;28(4):146–50. DOI: https://doi.org/10.1177/875512251202800403 Google Scholar PubMed WorldCat
  36. 36. Left Main Stent Thrombosis Complicated by Eptifibatide-Induced Acute Thrombocytopenia - PMC [Inter-net]. [cited 2024 Mar 21]. Available from: https://www-ncbi-nlm-nih-gov.qulib.idm.oclc.org/pmc/articles/PMC3066830/ Google Scholar PubMed WorldCat
  37. 37. Tanaka KA, Vega JD, Kelly AB, Hanson SR, Levy JH. Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost. 2003 Feb;1(2):392–4. DOI: https://doi.org/10.1046/j.1538-7836.2003.00056.x Google Scholar PubMed WorldCat
  38. 38. M. Adnan Raufi, Ayesha S. Baig, Rama Siddiqui, Nouman Akbar, Shakaib Jaffery. Eptifibatide Induced Severe Thrombocytopenia in an Asymptomatic Patient. JPP [Internet]. 2017 Jul 28 [cited 2024 Mar 21];5(7). Available from: http://www.davidpublisher.org/index.php/Home/Article/index?id=31759.html DOI: https://doi.org/10.17265/2328-2150/2017.07.009 Google Scholar PubMed WorldCat
  39. 39. Nandal S, Van Gaal W, Ponnuthurai FA. Eptifibatide-Induced Acute Profound Thrombocytopenia in a Pa-tient with Left Main Artery Plaque Rupture Complicated by Cardiogenic Shock and Gastrointestinal Bleed-ing. Journal of Clinical and Preventive Cardiology. 2021 Jun;10(2):74. DOI: https://doi.org/10.4103/jcpc.jcpc_67_20 Google Scholar PubMed WorldCat

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)